Derek Maetzold Sells 6,214 Shares of Castle Biosciences (NASDAQ:CSTL) Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Derek Maetzold sold 6,214 shares of Castle Biosciences stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $24.29, for a total value of $150,938.06. Following the completion of the sale, the insider owned 21,479 shares in the company, valued at $521,724.91. This represents a 22.44% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Castle Biosciences Trading Up 0.4%

Shares of Castle Biosciences stock traded up $0.10 during trading hours on Monday, hitting $24.21. The company’s stock had a trading volume of 187,688 shares, compared to its average volume of 397,864. The stock has a market cap of $734.29 million, a price-to-earnings ratio of -55.02 and a beta of 1.00. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.53 and a current ratio of 6.75. Castle Biosciences, Inc. has a twelve month low of $14.59 and a twelve month high of $44.28. The firm has a fifty day moving average of $21.54 and a 200-day moving average of $28.56.

Castle Biosciences (NASDAQ:CSTL) last issued its quarterly earnings data on Wednesday, May 6th. The company reported ($0.49) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.49). The firm had revenue of $84.23 million during the quarter, compared to the consensus estimate of $79.23 million. Castle Biosciences had a negative return on equity of 2.77% and a negative net margin of 3.78%. Research analysts forecast that Castle Biosciences, Inc. will post -1.56 EPS for the current year.

Hedge Funds Weigh In On Castle Biosciences

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Federated Hermes Inc. acquired a new position in shares of Castle Biosciences in the fourth quarter worth $26,000. Kemnay Advisory Services Inc. acquired a new stake in shares of Castle Biosciences in the fourth quarter valued at $35,000. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Castle Biosciences by 26.5% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,418 shares of the company’s stock valued at $55,000 after purchasing an additional 297 shares during the period. Caitong International Asset Management Co. Ltd grew its stake in Castle Biosciences by 140.4% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,750 shares of the company’s stock worth $68,000 after purchasing an additional 1,022 shares in the last quarter. Finally, CWM LLC grew its stake in Castle Biosciences by 20.5% during the 4th quarter. CWM LLC now owns 2,302 shares of the company’s stock worth $90,000 after purchasing an additional 391 shares in the last quarter. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on CSTL shares. Zacks Research downgraded shares of Castle Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, May 26th. Roth Mkm started coverage on shares of Castle Biosciences in a report on Wednesday, June 24th. They issued a “buy” rating and a $40.00 target price for the company. BTIG Research cut their target price on Castle Biosciences from $50.00 to $40.00 and set a “buy” rating on the stock in a research report on Wednesday, May 13th. Weiss Ratings cut Castle Biosciences from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, June 1st. Finally, KeyCorp set a $35.00 price objective on Castle Biosciences in a report on Friday, May 29th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $42.43.

Castle Biosciences Company Profile

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.